Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy

• Status: Completed
• Trial end date: 2020-02-29
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from matched sibling donor (MSD),matched unrelated donor (MUD) and haploidentical related donors(HRD) in the treatment of hematologic malignancy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanfang Hospital of Southern Medical University
• Collaborators: First Affiliated Hospital of Guangxi Medical University; Fujian Medical University; Fujian Medical University Union Hospital; Guangdong General Hospital; Guangdong Provincial People's Hospital; Guangxi Medical University; Guangzhou First Municipal People’s Hospital; Guangzhou First People's Hospital; Guangzhou General Hospital of Guangzhou Military Command; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Third Affiliated Hospital, Sun Yat-Sen University; Tongji Hospital; Wuhan Union Hospital, China; Xiangya Hospital of Central South University; Zhujiang Hospital
• Treatments: Antilymphocyte Serum; Cyclosporine; Cyclosporins; Methotrexate; Mycophenolate mofetil; Mycophenolic Acid

Criteria

Inclusion Criteria:

• Diagnosis of primary disease is acute leukemia/MDS/CML

• Receiving allo-HSCT

Exclusion Criteria:

• cardiac dysfunction (particularly congestive heart failure)

• hepatic abnormalities (bilirubin ≥ 3 mg/dL, aminotransferase> 2 times the upper limit of normal)

• renal dysfunction (creatinine clearance rate < 30 mL/min)

• Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)

• Patients with any conditions not suitable for the trial (investigators' decision)